Miro J Eigenmann
Overview
Explore the profile of Miro J Eigenmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van De Vyver A, Weinzierl T, Eigenmann M, Frances N, Herter S, Buser R, et al.
Mol Cancer Ther
. 2020 Dec;
20(2):357-366.
PMID: 33298591
Targeted T-cell redirection is a promising field in cancer immunotherapy. T-cell bispecific antibodies (TCB) are novel antibody constructs capable of binding simultaneously to T cells and tumor cells, allowing cross-linking...
2.
Eigenmann M, Frances N, Lave T, Walz A
J Pharmacokinet Pharmacodyn
. 2017 Nov;
44(6):617-630.
PMID: 29090407
Non-small cell lung cancer (NSCLC) patients greatly benefit from the treatment with tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR). However, emergence of acquired resistance inevitable occurs...
3.
Eigenmann M, Karlsen T, Krippendorff B, Tenstad O, Fronton L, Otteneder M, et al.
J Physiol
. 2017 Sep;
595(24):7311-7330.
PMID: 28960303
Key Points: For therapeutic antibodies, total tissue concentrations are frequently reported as a lump sum measure of the antibody in residual plasma, interstitial fluid and cells. In terms of correlating...
4.
Eigenmann M, Fronton L, Grimm H, Otteneder M, Krippendorff B
MAbs
. 2017 Jun;
9(6):1007-1015.
PMID: 28613103
Monoclonal antibodies are an important therapeutic entity, and knowledge of antibody pharmacokinetics has steadily increased over the years. Despite this effort, little is known about the extent of IgG antibody...
5.
Eigenmann M, Frances N, Hoffmann G, Lave T, Walz A
Mol Cancer Ther
. 2016 Sep;
15(12):3110-3119.
PMID: 27638857
We quantitatively compare the efficacy of two approved EGFR tyrosine kinase inhibitors, erlotinib and gefitinib, based on in vivo and in vitro data and show how a modeling approach can...